Latest Content

In this real-world study of patients with type 2 diabetes, treatment with semaglutide resulted in greater reductions in body weight and hemoglobin A1c than dulaglutide.

Coverage denials delay care, drive patients into debt, and erode trust in insurers—yet nearly half of affected patients never appeal.

Longer-term data support pimicotinib as an effective, well-tolerated option for a rare benign tumor that can cause significant joint disability.

Surgical therapy for diabetic gastroparesis was associated with meaningful reductions in HbA1c and lower rates of diabetes-related complications.

Acoramidis treatment sustained reductions in all-cause mortality, cardiovascular mortality, and first cardiovascular hospitalization through 54 months.

Implementation of surgeon-led Musculoskeletal Quality Collaborative protocols reduced high-cost consumable utilization without compromising patient safety. Systemwide collaboratives can reduce high-cost consumable utilization while maintaining low infection rates.

GLP-1s, care standards updates, nutritional guidance, and AI adoption in diabetes management are just a few of the hot topics to be presented and debated.

OLYMPIA-3 trial at ASCO 2026 shows odronextamab plus CHOP in higher-risk B-cell lymphoma delivers strong MRD-negative CRs with fewer visits.

The authors describe Medicare Advantage plans that screen for and provide supplemental benefits addressing social needs and explore how these benefits meet communities’ social needs.